Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Hengli botulinum toxin type A injection for moderate-to-severe dynamic forehead lines
CTR20240502Phase 3Active
- Sponsor
- Lanzhou Biotechnology Development
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A in Forehead lines, glabellar furrowing, sponsored by Lanzhou Biotechnology Development. Started Mar 2024; status: active.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
Forehead linesglabellar furrowing
Beyond the preview
Go deeper on CTR20240502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240502.